ChemoMetec ASOCSE:CHEMM -0.82%99 Days Payable is 211.45 as of Dec. 2025, which is 29% above its 10-year median of 164.44. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr523.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 87.17% on this metric.
The historical rank and industry rank for ChemoMetec AS's Days Payable or its related term are showing as below:
OCSE:CHEMM'
s Days Payable Range Over the Past 10 Years
Min: 106.4 Med: 164.44 Max: 266.61
Current: 266.61
During the past 13 years, ChemoMetec AS's highest Days Payable was 266.61. The lowest was 106.40. And the median was 164.44.
OCSE:CHEMM's Days Payable is ranked better than 87.17% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs OCSE:CHEMM: 266.61
ChemoMetec AS's Days Payable
increased
from Dec. 2024 (128.58) to Dec. 2025 (211.45).
It may suggest that ChemoMetec ASdelayed paying its suppliers.
ChemoMetec AS Days Payable Related Terms
ChemoMetec AS Days Payable Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, ChemoMetec AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Days Payable distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ChemoMetec AS's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a Days Payable of 211.45 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ChemoMetec AS and its competitors. This is 29% above median its historical median of 164.44. Over the past decade, ChemoMetec AS's Days Payable has ranged from 106.40 to 266.61. According to the industry distribution chart, ChemoMetec AS ranks #102 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is ChemoMetec AS's Days Payable too high?
ChemoMetec AS's current Days Payable of 211.45 is 29% above median its 10-year median of 164.44. Over the past 10 years, this metric has ranged from a low of 106.40 to a high of 266.61. The Medical Devices & Instruments industry median Days Payable is 68.07. ChemoMetec AS's value of 211.45 is 210.6% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #102 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #102 out of 795 companies for Days Payable. This places ChemoMetec AS in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. ChemoMetec AS's value of 211.45 is 210.6% above this benchmark. Historically, ChemoMetec AS's own Days Payable has ranged from 106.40 to 266.61 over the past decade. While the company's 10-year median is 164.44 vs. the industry median of 68.07, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Days Payable of 211.45 is 210.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Days Payable is 211.45, which is 29% above median its own 10-year median of 164.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Significantly Undervalued. The stock's GF Value™ is kr523.96, compared to a current price of kr362.20 — trading 30.9% below its estimated fair value. The current Days Payable is 211.45, which is 29% above median its 10-year median of 164.44 and 210.6% above the Medical Devices & Instruments industry median of 68.07. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Days Payable is 211.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr362.20 is trading 30.9% below its estimated GF Value™ of kr523.96.
GuruFocus considers ChemoMetec AS to be Significantly Undervalued.
Key valuation signals for OCSE:CHEMM:
Days Payable: 211.45 (29% above median its 10-year median of 164.44)
GF Value™: kr523.96 vs. price of kr362.20 (30.9% below fair value)
Industry Position: 210.6% above the Medical Devices & Instruments median (#102 of 795)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
